Inspiration Healthcare, the medical technology company developing best-in-class, specialist neonatal intensive care medical devices, has launched the SLE1500, the latest addition to its specialist neonatal ventilator range.
shutterstock / VectorMine
2116902446
neonatal concept
The SLE1500 is a compact respiratory support system that provides non-invasive ventilation (NIV) modes to meet the needs of the smallest and most vulnerable neonatal patients requiring respiratory support, helping to protect their fragile lungs.
NIV is considered the gold standard of care for preterm infants with respiratory distress syndrome (RDS) and is gradually becoming the first choice for respiratory support. The SLE1500 has been specifically designed to meet the special needs of vulnerable babies. The SLE1500 system offers six non-invasive delivery options in one machine; nasal Continuous Positive Airway Pressure (nCPAP) both flow and pressure controlled, high flow oxygen therapy, and manual flow for use with therapies like bubble CPAP, all of which can be augmented with Pulse Oximetry (SpO2) and / or automatic oxygen control (auto FiO2) through OxyGenie. Oxygenie, the company’s patented algorithmic oxygen controller, provides second by second control of oxygenation, allowing the baby to spend more time in its target oxygen saturation and staff to spend more time caring for the infant, thus improving outcomes.
Neil Campbell, CEO of Inspiration Healthcare, said: “We are delighted to extend our differentiated best-in-class ventilator product range with the launch of our new SLE1500 respiratory support system, which will enable us to support more babies. The need for non-invasive ventilation is paramount for the effective treatment and care of the smallest and most vulnerable neonates. The SLE1500 strengthens our ventilator product range and complements our range of respiratory consumables allowing us to offer better solutions to our customers worldwide.
“Our initial launch is focused on the UK and Australia, with other market introductions due to follow, subject to regulatory approvals. We are excited about the potential for the SLE1500, which demonstrates a key part of our growth strategy and our continued R&D commitment to pioneer innovative technologies to help save lives daily.”
